Cevimeline hydrochloride is a selective muscarinic receptor agonist used clinically as a sialogogue to treat xerostomia (dry mouth) associated with Sjögren's syndrome and radiation-induced salivary gland dysfunction; it stimulates salivary secretion, particularly from the parotid gland, and may help reduce the incidence of dental caries in patients with partial salivary gland loss; it also exhibits potential central nervous system effects by crossing the blood-brain barrier and inhibiting angiotensin II-induced water intake and neuronal activity in the subfornical organ.